ImmunoPrecise Antibodies Ltd.
IPA
$0.3918
-$0.0082-2.05%
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 17.70M | 17.74M | 18.16M | 17.55M | 16.78M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.70M | 17.74M | 18.16M | 17.55M | 16.78M |
| Cost of Revenue | 8.80M | 9.19M | 9.23M | 8.45M | 7.84M |
| Gross Profit | 8.90M | 8.55M | 8.93M | 9.11M | 8.94M |
| SG&A Expenses | 13.98M | 13.79M | 14.15M | 13.23M | 13.33M |
| Depreciation & Amortization | 1.93M | 2.01M | 2.20M | 2.66M | 2.90M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.18M | 28.22M | 28.33M | 27.08M | 27.23M |
| Operating Income | -10.48M | -10.48M | -10.17M | -9.52M | -10.45M |
| Income Before Tax | -22.16M | -21.83M | -21.21M | -11.69M | -12.54M |
| Income Tax Expenses | -1.89M | -1.66M | -1.40M | -1.39M | -934.20K |
| Earnings from Continuing Operations | -20.27 | -20.17 | -19.81 | -10.30 | -11.61 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.27M | -20.17M | -19.81M | -10.30M | -11.61M |
| EBIT | -10.48M | -10.48M | -10.17M | -9.52M | -10.45M |
| EBITDA | -7.82M | -7.48M | -6.70M | -5.87M | -6.23M |
| EPS Basic | -0.76 | -0.76 | -0.76 | -0.41 | -0.46 |
| Normalized Basic EPS | -0.26 | -0.26 | -0.25 | -0.23 | -0.25 |
| EPS Diluted | -0.76 | -0.76 | -0.76 | -0.41 | -0.46 |
| Normalized Diluted EPS | -0.26 | -0.26 | -0.25 | -0.23 | -0.25 |
| Average Basic Shares Outstanding | 107.71M | 104.63M | 102.55M | 100.93M | 100.08M |
| Average Diluted Shares Outstanding | 107.71M | 104.63M | 102.55M | 100.93M | 100.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
